COPIED
7 mins

OPINION

WHEN TRENDS TRAVEL FASTER THAN GOVERNANCE

From glass skin to treatment stacking, South Korea is shaping patient expectations. But does faster adoption mean better practice? Jen Vittanuova explores what UK aesthetics can learn, and why clinical judgement must keep pace with innovation.

South Korea’s influence on aesthetics offers plenty to learn from, but popularity should never replace clinical judgement. One practitioner considers where innovation ends and the need for greater scrutiny begins.

I keep seeing people say South Korea is ten years ahead of us in aesthetics. I don’t know if I’d go that far. Being quicker to adopt something doesn’t necessarily mean being clinically ahead, but there’s no denying its influence on what we’re doing, what patients are asking for and what we’re seeing on social media.

Korean skincare has become familiar on the UK high street. Then came glass skin, which seems to have gone from a Korean beauty ideal to something patients everywhere want to achieve. I understand the appeal. I like that we’ve moved some of the conversation away from filling lines and towards improving the skin itself.

Where I become cautious is when healthy skin becomes an expectation of completely smooth, poreless, reflective skin. Real skin has pores, texture, movement and variation. If a patient brings in an image shaped by treatments, make-up, lighting and filters as their expected outcome, there’s plenty to unpick before we discuss treatment.

WHEN A TREND BECOMES A TREATMENT REQUEST

The treatments are travelling just as quickly as the beauty ideals. Microtox, liquid microneedling and increasingly complicated combinations of devices, injectables and skin treatments are attracting attention.

Social media loves this because “I had ten treatments in one day in Korea” is considerably more interesting content than “I had a consultation, we decided I didn’t need half of these things and we’re going to review my skin in three months”.

That’s probably where my nurse brain starts fighting with my aesthetics brain.

I’m interested in new treatments. I wouldn’t still be working in aesthetics after all these years if I wasn’t. Being evidence-based doesn’t mean refusing to do anything until there are 20 years of data behind it. But we need to ask whether we’re adopting something because there’s a reasonable clinical rationale, or because patients are asking and everyone else appears to offer it.

Microtox illustrates the need for critical appraisal. A 2024 systematic review of intradermal botulinum toxin included ten studies involving 153 participants and reported improvements in several measures of skin quality. The authors called for further high-quality research, and subsequent correspondence questioned aspects of the analysis.

A meta-analysis is a starting point for examining the evidence, rather than a reason to stop asking questions. Promising findings still need to be considered alongside study size, methods and relevance to the patient in front of us.

“Liquid microneedling” needs similar scrutiny. The name sounds like a variation of an established procedure, but products marketed this way may use microscopic marine sponge-derived spicules rather than conventional needles.

A 2026 study involving 21 healthy women examined one microneedle cream over eight weeks, with participants receiving different levels of skincare instruction. It cannot validate every product or treatment marketed under the same label. A published paper only supports the claims its design and findings can actually sustain.

WHEN TEN TREATMENTS BECOMES THE SELLING POINT

I use combination treatments myself. Skin quality, pigmentation, vascular changes and volume loss can require different modalities, and combining them can make clinical sense.

What I find difficult is the idea that the number of treatments measures how advanced the plan is.

If somebody tells me they’ve had ten treatments in one day, my first thought isn’t “wow”. I want to know what they were, why each was indicated, how they might interact and whether there was any benefit to doing everything that day rather than staging treatment.

There’s also the question of what happens when the result isn’t what you expected.

If you’ve used an energy-based device, injected something, disrupted the skin barrier and applied active topical products, then the patient develops an unexpected reaction, establishing the cause may become considerably harder.

That can affect complication management, adverse event reporting and decisions about treating the patient again. Several simultaneous interventions introduce more variables, potentially making it harder to establish what went wrong. It matters for consent too. Is there evidence for the particular combination and sequence, or have individually plausible treatments simply been put together and assumed to be better? Has the patient been told about relevant uncertainty?

The more complicated the plan becomes, the more clinical reasoning it requires. I should be able to justify every treatment and explain why they needed to happen together. Otherwise, I’m not sure stacking is a treatment strategy at all.

Aesthetics isn’t a race where whoever adopts the most treatments first wins.

GOVERNANCE ISN’T THE BORING BIT

This is where the conversation becomes one about governance, and that doesn’t belong to one profession.

As a registered nurse and independent prescriber, I’m accountable to the NMC Code. It requires me to put people first, practise effectively, preserve safety and uphold professional standards. Other regulated healthcare professionals have their own professional obligations.

Being accountable means being able to explain what you’ve done, why you’ve done it and why it was appropriate for that patient.

Completing a course doesn’t automatically establish competence. Training matters, but so do knowledge, experience, judgement, understanding your limitations and knowing when not to treat. Being technically able to perform something isn’t the same as deciding whether you should.

Consent isn’t simply getting somebody to sign a form. If the evidence is emerging, the patient needs to understand that. If I’m combining treatments, they need to understand why, alongside realistic benefits, material risks and reasonable alternatives. Those alternatives may include staging treatment, doing less or doing nothing.

That last option sometimes seems to have disappeared from aesthetic medicine.

There’s an obvious commercial tension because aesthetics is both healthcare and business. Packages sell, and impressive treatment stacks make excellent content. Recognising that influence, and ensuring it doesn’t determine clinical decisions, is part of professional responsibility.

My expert witness work makes me look at this slightly differently too. After an adverse outcome, nobody is particularly interested in how fashionable the treatment was. They’re looking at the reasoning behind it.

Why was it chosen? Was the patient suitable? Were alternatives and material risks discussed? Were the records adequate, and was there a clear plan for managing complications?

Where treatments were combined, I’d also want to understand the sequencing, potential interactions and whether staging could have achieved the same outcome with less uncertainty.

“Because that’s the package” isn’t a clinical rationale.

WE HAVE OUR OWN PROBLEMS

None of this justifies looking at Korean practice from a position of assumed superiority. These questions apply wherever treatments are delivered, and social media offers only a selective picture of clinical practice.

The UK has its own problems around training, prescribing, competence and accountability. Professional registration provides an additional layer of oversight, but sound assessment, consent, records and complication planning should be expected of everyone providing aesthetic procedures.

Voluntary competency frameworks, including the JCCP’s, can help define expectations, but they don’t replace statutory regulation.

For me, governance should ask more than whether we’re legally or technically allowed to perform something. “Should I do this to this patient, today, alongside everything else I’m planning?” is the more useful question.

We should also be interested in the expectations behind the beautiful images. Beauty ideals have social and commercial influences, in South Korea as elsewhere. Admiring an aesthetic doesn’t mean accepting every pressure that accompanies it, or teaching patients that normal skin texture needs correcting.

ARE THEY REALLY TEN YEARS AHEAD?

I’m still not convinced “ahead” is the right word.

There’s plenty to learn from South Korea’s emphasis on skin quality and maintenance, and its appetite for technology and combination approaches. What I don’t think we need to do is follow every trend at the same speed.

We can be interested in a treatment performed in Seoul and still question its evidence. We can learn from combination approaches without making ten treatments in a day an aspiration.

Aesthetics isn’t a race where whoever adopts the most treatments first wins. Being able to explain a decision, support it with evidence, obtain informed consent and manage the consequences matters considerably more.

The question I keep returning to is simple: if this treatment didn’t have a catchy name, wasn’t all over social media and the patient hadn’t already decided they wanted it, would I still recommend it?

If the answer is yes, brilliant. Then I need to understand the evidence and use it appropriately. If it’s no, perhaps we need to ask who the treatment is actually for.

Because when everything goes beautifully, nobody is particularly interested in your governance. When it doesn’t, it’s the first thing everyone wants to see.

Scan for references:

JEN VITTANUOVA

Jen Vittanuova is a Registered Nurse Prescriber, aesthetic practitioner and expert witness with more than 25 years’ experience across nursing, cosmetic surgery and aesthetic medicine. Her clinical background includes maxillofacial and ENT head and neck surgery, breast and bowel surgery, wound care and advanced nursing practice, before establishing her own medical aesthetics practice.

This article appears in Nov/dec 2026

Go to Page View
This article appears in...
Nov/dec 2026
Go to Page View
DEAR READERS
There’s always something new to talk about in
MEET THE EXPERTS
The Aesthetic Medicine editorial board’s clinical expertise and diverse range of specialities help ensure the magazine meets the needs of the readers. In this issue, we have received guidance from the following members:
SKIN QUALITY REDEFINED
As skin quality becomes an increasingly prominent focus in aesthetic practice, Teoxane introduces babyGLOW™ and babyGLOW™ for HIM, two protocols designed to address skin revitalisation with a focus on precision and natural-looking results. 1
HOT OFF THE PRESS
UK government launches consultation on high-risk cosmetic procedures
OUT & ABOUT
REJURAN PRESS TRIP Seoul and Gangneung, South Korea
JEN VITTANUOVA IS… LEGALLY AESTHETIC
Funny, frank and fiercely attached to her patients, Jen Vittanuova is bringing her experience as an aesthetic nurse and expert witness into education. With Legally Blonde as her muse, she is making the case for better consent, sharper records and safer clinics, discovers Kezia Parkins .
CASE STUDY: CHRONIC ACNE AND SCARRING TRANSFORMATION
Treating chronic acne and post-acne concerns with a personalised combination approach
PDRN VS PN: WHAT AESTHETIC PRACTITIONERS NEED TO KNOW
As PDRN moves into topical skincare and injectable polynucleotides gain prominence in clinics, confusion surrounding the two categories is growing. Ellen Cummings examines their proposed mechanisms, evidence and implications for clinical practice.
BEYOND THE SURFACE
A multi-layer approach to skin rejuvenation with RF Microneedling
NEXT UP
Claudia McGloin asks: what should really define the next trend in regenerative injectables?
THE EVOLVING BOOB JOB
Consultant plastic surgeon Paul Banwell on awake surgery, tissue preservation, implant innovation and the future of the “boob job”.
BEYOND THE TEMPLATE
Dr Ahmed El Muntasar argues that safe, individualised aesthetic care requires practitioners to understand anatomical variation, assess skin characteristics and question whose beauty standards shape treatment.
CLINIC TO COSMETIC COUNTER
Dr Farah Latif and Prof Ali Al -Hussaini ask: are professional treatments becoming beauty products?
UNDERSTANDING ICHTHYOSIS VULGARIS
Dr Kemi Fabusiwa and Professor Edel O’Toole explain how to recognise, manage and treat ichthyosis vulgaris, from protecting the skin barrier to supporting patients with long-term care.
RETHINKING THE RESEARCH
Dr Jordan Faulkner on why practitioners need to question the evidence behind the treatments they offer.
PRACTICALLY PERFECT?
As Practical Magic 2 hits cinemas, 28 years after the original, its female stars have ignited a debate around ageing: don’t have too much work done, but don’t show any signs of ageing. Vicky Eldridge asks: how can women in aesthetic medicine help to change the narrative?
PRECISION FIRST
Emma Wedgwood looks into why the next big thing in 2027 will not be a treatment, but precision.
WHEN TRENDS TRAVEL FASTER than governance
From glass skin to treatment stacking, South Korea is shaping patient expectations. But does faster adoption mean better practice? Jen Vittanuova explores what UK aesthetics can learn, and why clinical judgement must keep pace with innovation.
THE UNSEEN WORK OF EXCELLENCE
Why clinical excellence depends on consistent standards, practical experience and knowing when to keep learning.
THE PURSUIT OF EXPERTISE OR THE PURSUIT OF RECOGNITION?
Amy Bird questions whether aesthetic medicine is prioritising visibility and recognition over clinical knowledge.
LEAD WITH THE CONDITION NOT THE CURE
Why condition-led websites win more consultations and keep you on the right side of the ASA.
ASK THE EXPERTS
Which health factors could influence treatment outcomes?
THE INTELLIGENT CLINIC
Dr Askari Townshend looks into why the future of aesthetics will be driven by data.
HOW AI SEARCH IS CHANGING WHERE PATIENTS FIND AESTHETIC CLINICS
AI is changing how patients discover aesthetic clinics. Panita Vig explains what AI search means for clinic visibility and the practical steps practitioners can take now to stay discoverable.
RETHINKING CLINICAL STYLE
Ditching the traditional clinical look, Emma Wedgwood shares how she transformed her treatment room into a space that reflects her style and personality.
PROTECT YOUR PRACTICE
Asking the right questions now can help protect your practice, reputation and clients later,
HYDRAFACIAL NANO-NEEDLING
Connie Cooper visited the Hydrafacial flagship to try their latest treatment: Hydrafacial Deluxe with SkinStylus Nano-Needling.
DOUBLE CHIN TIGHTENING WITH XERF
Contributing reporter Anna Dobbie visits the Seriderm Training Centre to experience XERF, a non-invasive radiofrequency treatment that tightens and firms the skin beneath her chin.
PRODUCT NEWS
AlumierMD AlumierMD has expanded its Biocellulose range with
5 MINUTES WITH ... IAIN DE HAVILLAND
Founder of NADclinic Group, Iain De Havilland discusses evolution of NAD+ therapy and the growing role of personalised longevity medicine in aesthetics.
5 ANATOMY EXPERTS TO FOLLOW
These five specialists are putting facial anatomy, clinical knowledge and education at the forefront of aesthetics.
Looking for back issues?
Browse the Archive >

Previous Article Next Article